Recommendation from Agri and Healthcare Sector

The scrips in this column have been recommended with a 15-day investment horizon in mind and carry high risk. Therefore, investors are advised to take into account their risk appetite before investing, as fundamentals may or may not back the recommendations.[EasyDNNnews:PaidContentStart]

Tata Consumer Products Ltd.
CMP - ₹1,210.80
BSE CODE 500800
Volume 94,297
Face Value ₹1
Target ₹1,308- ₹1,332
Stoploss ₹1,125 (CLS)

Tata Consumer Products Ltd (TCPL), part of the Tata Group, is a leading FMCG company in India. Formed through the merger of Tata Global Beverages and Tata Chemicals’ consumer business, the company owns well-known brands such as Tata Tea, Tetley, Tata Salt, Sampann, and Tata Coffee. TCPL caters to domestic and international markets, focusing on branded, value-added products across everyday consumption segments. During Q2FY26, the company posted a notable performance, with revenue climbing 18 per cent year-on-year to ₹4,966 crore. Profitability also improved, as net profit surged to ₹407 crore compared with ₹367 crore in the corresponding quarter of the previous year. Investor optimism is rising ahead of the Union Budget, with expectations of policy support for consumption-led sectors. Measures to boost rural demand and discretionary spending could benefit Tata Consumer Products Ltd whose strong brand portfolio positions it well to capture improving demand trends. Hence, we recommend BUY.

Fortis Healthcare Ltd.
CMP - ₹945.45
BSE CODE 532843
Volume 1,14,037
Face Value ₹10
Target ₹1,020 - ₹1,040
Stoploss ₹880 (CLS)

Fortis Healthcare Ltd is one of India’s leading integrated healthcare service providers, operating a strong network of hospitals, diagnostics, and day-care specialty facilities. The company continues to benefit from rising healthcare demand, higher occupancy levels, and a growing preference for quality private healthcare services in India. In the second quarter of FY26, the company delivered a robust set of numbers, reporting a 17 per cent year-onyear growth in revenue to ₹2,331 crore. Earnings strengthened sharply, with net profit increasing to ₹329 crore from ₹193 crore in the same quarter last year. The company has announced the acquisition of People Tree Hospital in Bengaluru for ₹4.3 billion, a move that is expected to strengthen its footprint in the South Indian healthcare market. Separately, CRISIL Ratings has reaffirmed Fortis Healthcare’s credit ratings at ‘CRISIL AA+/Stable/CRISIL A1+’, underscoring its strong credit profile. Hence, considering the company’s robust financial performance and improving operating metrics, we recommend BUY.

[EasyDNNnews:PaidContentEnd] [EasyDNNnews:UnPaidContentStart]

[EasyDNNnews:UnPaidContentEnd]